GU Cancers 2021 | EV-201: enfortumab vedotin for cisplatin-ineligible bladder cancer

Arjun Balar, MD, NYU Langone Health Perlmutter Cancer Center, New York City, NY, shares an update on the EV-201 trial (NCT03219333) investigating enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who have previously received PD-1/L-1 inhibitor treatment. Cohort 1 of the EV-210 trial led to accelerated approval of enfortumab vedotin in adult patients with locally advanced or metastatic urothelial cancer, who have previously received a PD-1/L-1 inhibitor and platinum-based chemotherapy. Cohort 2 investigated enfortumab vedotin in cisplatin-ineligible patients who have received a prior PD-1/L-1 inhibitor. 91 patients were enrolled in cohort 2. Cohort 2 reported an overall response rate (ORR) of 52% and a complete response rate of 20% among treated patients. The median duration of response was 10.9 months, the median progression-free survival (PFS) was 5.8 months, and the median overall survival (OS) was 14.7 months. 9% of patients discontinued enfortumab vedotin treatment due to progressive disease. This interview took place during the 2021 Genitourinary Cancers Symposium.